The Effects of 5-HT4 Receptor Agonist, Mosapride Citrate, on Visceral Hypersensitivity in a Rat Model

被引:4
|
作者
Lee, Jae Woong [2 ]
Sung, Ki Woon [3 ]
Lee, Oh Young [4 ]
Lee, Seo Eun [3 ,5 ]
Sohn, Chong Il [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Div Gastroenterol,Dept Internal Med, Seoul 110746, South Korea
[2] Hanil Gen Hosp, Div Gastroenterol, Seoul, South Korea
[3] Hanyang Univ, Coll Med, Dept Physiol, Seoul 133791, South Korea
[4] Hanyang Univ, Coll Med, Dept Internal Med, Seoul 133791, South Korea
[5] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Biomed Sci, Seoul 133791, South Korea
关键词
Mosapride citrate; Colorectal distension; Visceral hypersensitivity; Irritable bowel; IRRITABLE-BOWEL-SYNDROME; IN-VITRO; INHIBITORY CONTROLS; ABDOMINAL-PAIN; COLORECTAL DISTENSION; RECTAL DISTENSION; SENSITIVITY; SEROTONIN; COLON; TEGASEROD;
D O I
10.1007/s10620-012-2101-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Mosapride citrate is known to affect gastric motility. However, whether mosapride citrate has any effect on visceral pain in the colon or rectum is not certain. The aim of this study was to assess the effects of mosapride citrate on visceral pain in a rat visceral hypersensitivity model. The perception of visceral pain was evaluated by the visceromotor response to colorectal distension observed on electromyographs of the abdominal musculature in urethane-anesthetized rats. Visceral hypersensitivity was induced by the intrarectal instillation of 4% acetic acid or 1.5% zymosan. Mosapride citrate was administered intraperitoneally 3 h later. VMRs to CRD were recorded prior to the instillation of acetic acid or zymosan and before and after mosapride citrate treatment. The intracolonic instillation of acetic acid resulted in a significant increase in VMRs of the abdominal muscles to CRD, compared with the pretreatment state (174 +/- A 24%, P < 0.05). The intracolonic instillation of zymosan resulted in a significant increase in VMRs of the abdominal muscles to CRD, compared with the pretreatment state (144 +/- A 9%, P < 0.05). Intraperitoneal injection of mosapride citrate resulted in a significant reduction in the VMRs to CRD in an acetic acid-induced visceral hypersensitivity rat model (61 +/- A 9%, P < 0.05). The intraperitoneal injection of mosapride citrate also resulted in a significant reduction in the VMRs to CRD in a zymosan-induced visceral hypersensitivity rat model (67 +/- A 9%, P < 0.05). Mosapride citrate diminished visceral pain in rats.
引用
收藏
页码:1517 / 1524
页数:8
相关论文
共 50 条
  • [21] A selective, high affinity 5-HT2B receptor antagonist inhibits visceral hypersensitivity in rats
    Ohashi-Doi, K.
    Himaki, D.
    Nagao, K.
    Kawai, M.
    Gale, J. D.
    Furness, J. B.
    Kurebayashi, Y.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2010, 22 (02) : e69 - e76
  • [22] Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model
    Langlois, A
    Pascaud, X
    Junien, JL
    Dahl, SG
    Riviere, PJM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 318 (01) : 141 - 144
  • [23] The pharmacology of TD-8954, a potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties
    Beattie, David T.
    Armstrong, Scott R.
    Vickery, Ross G.
    Tsuruda, Pamela R.
    Campbell, Christina B.
    Richardson, Carrie
    McCullough, Julia L.
    Daniels, Oranee
    Kersey, Kathryn
    Li, Yu-Ping
    Kim, Karl H. S.
    FRONTIERS IN PHARMACOLOGY, 2011, 2
  • [24] Repeated corticosterone administration increases excitatory effect of 5-HT4 receptor agonist in the rat hippocampus
    Zahorodna, A
    Tokarski, K
    Bijak, M
    POLISH JOURNAL OF PHARMACOLOGY, 2000, 52 (02): : 107 - 109
  • [25] The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT4 receptor agonist, DSP-6952
    Tsubouchi, Tadashi
    Kunimatsu, Takeshi
    Tsujimoto, Shinji
    Kiyoshi, Akihiko
    Katsura, Yasunori
    Oku, Seiko
    Chihara, Kazuhiro
    Mine, Yukiko
    Yamada, Toru
    Shimizu, Isao
    Bando, Kiyoko
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 826 : 96 - 105
  • [26] Protective actions of a luminally acting 5-HT4 receptor agonist in mouse models of colitis
    Hurd, Molly
    Haag, Melody M.
    Kwasnik, Matthew J.
    Wykosky, Jill
    Lavoie, Brigitte
    Mawe, Gary M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (11)
  • [27] Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans
    Camilleri, M.
    Vazquez-Roque, M. I.
    Burton, D.
    Ford, T.
    Mckinzie, S.
    Zinsmeister, A. R.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2007, 19 (01) : 30 - 38
  • [28] The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat
    McCullough, JL
    Armstrong, SR
    Hegde, SS
    Beattie, DT
    PHARMACOLOGICAL RESEARCH, 2006, 53 (04) : 353 - 358
  • [29] 5-HT4 Receptor Agonist Effects on Functional Connectivity in the Human Brain: Implications for Procognitive Action
    de Cates, Angharad N.
    Martens, Marieke A. G.
    Wright, Lucy C.
    Gibson, Daisy
    Spitz, Gershon
    van Praag, Cassandra D. Gould
    Suri, Sana
    Cowen, Philip J.
    Murphy, Susannah E.
    Harmer, Catherine J.
    BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2023, 8 (11) : 1124 - 1134
  • [30] Effects of 5-HT4 receptor agonists and antagonists in learning
    Meneses, A
    Hong, E
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 56 (03) : 347 - 351